Literature DB >> 12234313

Inflammatory signals associated with hemodialysis.

Kayser Caglar1, Youming Peng, Lara B Pupim, Paul J Flakoll, Deanna Levenhagen, Raymond M Hakim, T Alp Ikizler.   

Abstract

BACKGROUND: Inflammation is highly prevalent in chronic hemodialysis patients. Because hemodialysis involves the contact of blood with "foreign" surfaces, and the documented activation of several humoral and cellular pathways during the procedure, the hemodialysis procedure has been suggested as a potential source of inflammation in this patient population. Earlier studies did not provide clear-cut evidence of the potential contribution of the hemodialysis procedure to inflammation, as assessed by markers of inflammation such as cytokine levels and acute-phase protein production.
METHODS: Nine patients were studied using primed-constant infusion of l-(l-13C) leucine 2 hours before, during, and 2 hours after a single hemodialysis session. We evaluated the effects of hemodialysis on induction of interleukin-6 (IL-6) production as well as the fractional synthetic rates (FSR) of albumin and fibrinogen, two well-known acute-phase proteins.
RESULTS: During hemodialysis, albumin FSR and fibrinogen FSR increased significantly compared to the measurements obtained during baseline period. During this period, albumin and fibrinogen FSR increased 64% and 34%, respectively, compared to baseline (P < 0.05). While the increase in IL-6 concentration was modest during hemodialysis (14%), the levels further increased at the end of the 2-hour post-hemodialysis period (68% higher compared to baseline, P < 0.05). Fibrinogen FSR also demonstrated a further increase during the post-dialysis period (17% higher compared to the intradialytic period and 58% higher compared to baseline), while albumin FSR stabilized during this period.
CONCLUSIONS: The results provide clear evidence of hemodialysis-induced inflammatory response. The process is most notable during the 2-hour post-hemodialysis period.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234313     DOI: 10.1111/j.1523-1755.2002.kid556.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

1.  Pulmonary hypertension in end-stage renal disease and post renal transplantation patients.

Authors:  Esam H Alhamad; Mohammed Al-Ghonaim; Hussam F Alfaleh; Joseph P Cal; Nazmi Said
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

2.  Procalcitonin serum levels in children undergoing chronic haemodialysis.

Authors:  Fleur Lorton; Frédérique Veinberg; Dominique Ielsch; Georges Deschênes; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

3.  Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients.

Authors:  Serpil M Deger; Adriana M Hung; Jorge L Gamboa; Edward D Siew; Charles D Ellis; Cindy Booker; Feng Sha; Haiming Li; Aihua Bian; Thomas G Stewart; Roy Zent; William E Mitch; Naji N Abumrad; T Alp Ikizler
Journal:  JCI Insight       Date:  2017-11-16

4.  Quality of life and protein-energy wasting in kidney transplant recipients.

Authors:  Akos Ujszaszi; Maria E Czira; Katalin Fornadi; Marta Novak; Istvan Mucsi; Miklos Z Molnar
Journal:  Int Urol Nephrol       Date:  2012-01-14       Impact factor: 2.370

5.  Levels of hepatocyte growth factor in serum correlate with quality of life in hemodialysis patients.

Authors:  Ewa Baum; Krzysztof Pawlaczyk; Beata Maćkowiak; Patrycja Sosinska; Monika Matecka; Barbara Kolodziejczak; Michał Musielak; Andrzej Breborowicz
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 6.  Diets and enteral supplements for improving outcomes in chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh; Noël J Cano; Klemens Budde; Charles Chazot; Csaba P Kovesdy; Robert H Mak; Rajnish Mehrotra; Dominic S Raj; Ashwini R Sehgal; Peter Stenvinkel; T Alp Ikizler
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

7.  IL-1β receptor antagonist reduces inflammation in hemodialysis patients.

Authors:  Adriana M Hung; Charles D Ellis; Ayumi Shintani; Cindy Booker; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2011-02-10       Impact factor: 10.121

8.  Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.

Authors:  Annis M Marney; Ji Ma; James M Luther; T Alp Ikizler; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

9.  Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Joshua J Zaritsky; Parta Hatamizadeh; Jennie Jing; Keith C Norris; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

Review 10.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.